Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 9, 2025
September 8, 2025
07142307-dadf-4c95-927c-469f261c1c58
Related Documents
E6(R3) Good Clinical Practice (GCP)
Guidance DocumentSeptember 8, 2025Center for Drug Evaluation and Research
Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications
Guidance DocumentSeptember 11, 2025Center for Drug Evaluation and Research
Classification Categories for Certain Supplements Under BsUFA III
Guidance DocumentSeptember 8, 2025Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.